Suppr超能文献

组胺 H(3)受体拮抗剂的合成 - 羟脯氨酸立体化学的调控、六氢哌嗪的非对映选择性拆分以及无萃取的三乙酰氧基硼氢化钠反应后处理。

Synthesis of a histamine H(3) receptor antagonist-manipulation of hydroxyproline stereochemistry, desymmetrization of homopiperazine, and nonextractive sodium triacetoxyborohydride reaction workup.

机构信息

Johnson & Johnson Pharmaceutical Research and Development, L.L.C., 3210 Merryfield Row, San Diego, California 92121, USA.

出版信息

J Org Chem. 2010 Jul 2;75(13):4463-71. doi: 10.1021/jo100629z.

Abstract

We have recently completed the synthesis of 1-[2-(4-cyclobutyl-[1,4]diazepane-1-carbonyl)-4-(3-fluoro-phenoxy)-pyrrolidin-1-yl]-ethanone, a hydroxyproline-based H(3) receptor antagonist, on 100 g scale. The synthesis proceeds through four steps and route selection was driven by a desire to minimize the cost-of-goods. Naturally occurring trans-4-hydroxy-L-proline was chosen as the precursor to the target's core, which necessitated an inversion at both stereogenic centers. The inversions were accomplished through strategic employment of La Rosa's lactone and a late-stage Mitsunobu reaction. A first generation synthesis that employed N-Boc-homopiperazine was improved in a second generation approach wherein homopiperazine was directly desymmetrized. Finally, the water solubility of a key intermediate necessitated the development of a nonextractive workup for the sodium triacetoxyborohydride reduction.

摘要

我们最近在 100 克规模上完成了 1-[2-(4-环丁基-[1,4]二氮杂环庚烷-1-羰基)-4-(3-氟-苯氧基)-吡咯烷-1-基]-乙酮的合成,这是一种基于羟脯氨酸的 H(3)受体拮抗剂。该合成通过四个步骤进行,路线选择的驱动力是降低产品成本。天然存在的反式-4-羟基-L-脯氨酸被选为目标物核心的前体,这需要在两个手性中心都进行反转。通过战略性地使用 La Rosa 内酯和后期的 Mitsunobu 反应来实现反转。第一代合成采用 N-Boc-高哌嗪,在第二代方法中得到了改进,其中高哌嗪直接进行了非对称化。最后,由于关键中间体的水溶性,需要开发一种非萃取的工作流程来进行三乙酰氧基硼氢化钠还原。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验